Idexx Laboratories initiated with a Neutral at UBS

UBS analyst Andrea Alfonso initiated coverage of Idexx Laboratories (IDXX) with a Neutral rating and $720 price target Top-line estimates already sufficiently credit new cytology launches and the customer ramp outside the U.S., the analyst tells investors in a research note. The firm’s survey work suggests mixed adoption for the inVue analyzer but even with conservative inputs, UBS is modeling inVue alone driving 1%-2% annual contribution on top of platforms still growing, suggesting multiple levers.